ELX-02

DRUG8 trials

Sponsors

Eloxx Pharmaceuticals, Inc.

Conditions

Alport SyndromeCystic FibrosisCystinosisGenetic DiseaseGenetic DiseasesImpaired Renal FunctionNonsense MutationNonsense Mutations

Phase 1

Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

TerminatedNCT02807961

Eloxx Pharmaceuticals, Inc.Genetic Diseases, Nonsense Mutations

Start: 2016-07-31End: 2017-05-31Updated: 2019-10-22

Phase 1 Study of ELX-02 in Healthy Adults

CompletedNCT03292302

Eloxx Pharmaceuticals, Inc.Genetic Disease, Nonsense Mutation

Start: 2017-09-26End: 2017-12-15Updated: 2023-08-22

Phase 1 Study of ELX-02 in Healthy Adult Subjects

CompletedNCT03309605

Eloxx Pharmaceuticals, Inc.Genetic Disease, Nonsense Mutation

Start: 2017-10-11End: 2019-07-17Updated: 2021-03-16

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

CompletedNCT03776539

Eloxx Pharmaceuticals, Inc.Impaired Renal Function

Start: 2019-01-04End: 2019-08-07Updated: 2021-04-13

Phase 2

A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis

TerminatedNCT04069260

Eloxx Pharmaceuticals, Inc.Cystinosis, Genetic Disease, Nonsense Mutation

Start: 2019-08-02End: 2019-12-17Updated: 2020-05-27

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

CompletedNCT04126473

Eloxx Pharmaceuticals, Inc.Cystic Fibrosis

Start: 2019-11-05End: 2022-04-06Updated: 2023-08-21

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

CompletedNCT04135495

Eloxx Pharmaceuticals, Inc.Cystic Fibrosis

Start: 2019-11-25End: 2022-10-03Updated: 2022-11-22

A Study of ELX-02 in Patients With Alport Syndrome

CompletedNCT05448755

Eloxx Pharmaceuticals, Inc.Alport Syndrome

Start: 2022-11-28End: 2023-09-11Updated: 2026-02-24